OptimizeRx price to free cash flow OPRX

Market value divided by free cash flow over the last twelve months, since 2013.

Today, Oct 23, 2026: 9.4×
7-year median: 40.4×
Against its 7-year history: 14th; percentile: 0 is its lowest day, 100 its highest
7-year range: 6.0× to 224×
Peer median: 7.9×

OptimizeRx's price to free cash flow is 9.4× as of Oct 23, 2026.

That is below its 7-year median of 40.4×, lower than on 86% of days in the last 7 years.

Over that time it ranged from 6.0× in Mar 2026 to 224× in Jan 2020.

The median for 10 credit services stocks of a similar size is 7.9×.

Price to free cash flow over time

median 40.4×

The dashed line is the 7-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	9.4×	6.0×	20.9×
2025	19.8×	19.8×	49.0×
2024	113×	113×	170×
2023	151×	20.5×	151×
2022	44.9×	44.6×	181×
2021	n/m a value too high to mean anything
2020	137×	137×	224×
2019	204×	66.2×	217×
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	22.7×	22.7×	90.9×
2013	80.0×	47.1×	80.0×

Against its peers

Companies in Financial - Credit Services nearest OptimizeRx's size, closest first, today.

Company	Price to free cash flow
OPRXOptimizeRx	9.4×
DHXDHI	10.0×
CPSSConsumer Portfolio Services	0.6×
SNFCASecurity National Financial	3.2×
IMXIInternational Money Express	31.8×
MACIMelar Acquisition Corp. I/Cayman	n/m
POWWOutdoor	30.4×
IRHOIron Horse Acquisition II	n/m
RMRegional Management	0.9×
LSAKLesaka Technologies	11.0×
RMNIRimini Street	5.9×
Peer median	7.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on OptimizeRx

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.